| Product Code: ETC13157829 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
North America Onco-hematology Molecular Testing Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 North America Onco-hematology Molecular Testing Market Overview |
3.1 North America Regional Macro Economic Indicators |
3.2 North America Onco-hematology Molecular Testing Market Revenues & Volume, 2021 & 2031F |
3.3 North America Onco-hematology Molecular Testing Market - Industry Life Cycle |
3.4 North America Onco-hematology Molecular Testing Market - Porter's Five Forces |
3.5 North America Onco-hematology Molecular Testing Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 North America Onco-hematology Molecular Testing Market Revenues & Volume Share, By Blood Cancer Type, 2021 & 2031F |
3.7 North America Onco-hematology Molecular Testing Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.8 North America Onco-hematology Molecular Testing Market Revenues & Volume Share, By Blood Cancer Biomarker, 2021 & 2031F |
3.9 North America Onco-hematology Molecular Testing Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 North America Onco-hematology Molecular Testing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 North America Onco-hematology Molecular Testing Market Trends |
6 North America Onco-hematology Molecular Testing Market, 2021 - 2031 |
6.1 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Blood Cancer Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Chronic Myeloid Leukemia, 2021 - 2031 |
6.1.3 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Myeloproliferative Neoplasms, 2021 - 2031 |
6.1.4 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Acute Myeloid Leukemia, 2021 - 2031 |
6.1.5 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Acute Lymphoblastic Leukemia, 2021 - 2031 |
6.2 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Technology, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By qPCR, 2021 - 2031 |
6.2.3 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By dPCR, 2021 - 2031 |
6.2.4 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Next-Generation Sequencing, 2021 - 2031 |
6.2.5 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Others, 2021 - 2031 |
6.3 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Blood Cancer Biomarker, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By BCR-ABL1 Mbcr, 2021 - 2031 |
6.3.3 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By JAK2, 2021 - 2031 |
6.3.4 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By CALR, 2021 - 2031 |
6.3.5 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By MPL, 2021 - 2031 |
6.3.6 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By PML-RARA, 2021 - 2031 |
6.3.7 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By NPM1, 2021 - 2031 |
6.3.8 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By RUNX1-RUNX1T1, 2021 - 2031 |
6.3.9 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By CBFB-MYH11, 2021 - 2031 |
6.4 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By End-user, 2021 - 2031 |
6.4.2 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By National Reference Lab / Specialty Lab, 2021 - 2031 |
6.4.3 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By University Hospital / Oncology Center, 2021 - 2031 |
6.4.4 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Community Hospital / IDN (Regional/National), 2021 - 2031 |
7 North America Onco-hematology Molecular Testing Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Blood Cancer Type, 2021 - 2031 |
7.2.1 United States (US) Onco-hematology Molecular Testing Market, Revenues & Volume, By Blood Cancer Type, 2021 - 2031 |
7.2.2 Canada Onco-hematology Molecular Testing Market, Revenues & Volume, By Blood Cancer Type, 2021 - 2031 |
7.2.3 Rest of North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Blood Cancer Type, 2021 - 2031 |
7.3 North America Onco-hematology Molecular Testing Market Revenues & Volume Share, By Technology, 2021 & 2031F |
7.3.1 United States (US) Onco-hematology Molecular Testing Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.3.2 Canada Onco-hematology Molecular Testing Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.3.3 Rest of North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.4 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Blood Cancer Biomarker, 2021 - 2031 |
7.4.1 United States (US) Onco-hematology Molecular Testing Market, Revenues & Volume, By Blood Cancer Biomarker, 2021 - 2031 |
7.4.2 Canada Onco-hematology Molecular Testing Market, Revenues & Volume, By Blood Cancer Biomarker, 2021 - 2031 |
7.4.3 Rest of North America Onco-hematology Molecular Testing Market, Revenues & Volume, By Blood Cancer Biomarker, 2021 - 2031 |
7.5 North America Onco-hematology Molecular Testing Market, Revenues & Volume, By End-user, 2021 - 2031 |
7.5.1 United States (US) Onco-hematology Molecular Testing Market, Revenues & Volume, By End-user, 2021 - 2031 |
7.5.2 Canada Onco-hematology Molecular Testing Market, Revenues & Volume, By End-user, 2021 - 2031 |
7.5.3 Rest of North America Onco-hematology Molecular Testing Market, Revenues & Volume, By End-user, 2021 - 2031 |
8 North America Onco-hematology Molecular Testing Market Key Performance Indicators |
9 North America Onco-hematology Molecular Testing Market - Export/Import By Countries Assessment |
10 North America Onco-hematology Molecular Testing Market - Opportunity Assessment |
10.1 North America Onco-hematology Molecular Testing Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 North America Onco-hematology Molecular Testing Market Opportunity Assessment, By Blood Cancer Type, 2021 & 2031F |
10.3 North America Onco-hematology Molecular Testing Market Opportunity Assessment, By Technology, 2021 & 2031F |
10.4 North America Onco-hematology Molecular Testing Market Opportunity Assessment, By Blood Cancer Biomarker, 2021 & 2031F |
10.5 North America Onco-hematology Molecular Testing Market Opportunity Assessment, By End-user, 2021 & 2031F |
11 North America Onco-hematology Molecular Testing Market - Competitive Landscape |
11.1 North America Onco-hematology Molecular Testing Market Revenue Share, By Companies, 2022 |
11.2 North America Onco-hematology Molecular Testing Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here